AR053158A1 - Compuestos para inhibir la actividad de quinesina de ksp - Google Patents
Compuestos para inhibir la actividad de quinesina de kspInfo
- Publication number
- AR053158A1 AR053158A1 ARP060100851A ARP060100851A AR053158A1 AR 053158 A1 AR053158 A1 AR 053158A1 AR P060100851 A ARP060100851 A AR P060100851A AR P060100851 A ARP060100851 A AR P060100851A AR 053158 A1 AR053158 A1 AR 053158A1
- Authority
- AR
- Argentina
- Prior art keywords
- nr4c
- nr4r5
- alkyl
- heteroaryl
- nr4or7
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 17
- 125000001072 heteroaryl group Chemical group 0.000 abstract 17
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 11
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 10
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 10
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000005103 alkyl silyl group Chemical group 0.000 abstract 3
- -1 arlo Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
- 102000010638 Kinesin Human genes 0.000 abstract 1
- 108010063296 Kinesin Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas que comprenden estos compuestos para tratar enfermedades proliferativas celulares trastornos asociados con la actividad de quinesina de KSP. Reivindicacion 1: Un compuesto representado por la formula estructural (1) o una de sus sales, sus solvatos o ésteres aceptables desde el punto de vista farmacéutico, en los que: el anillo Y es un anillo de 5 a 6 miembros o un heteroarilo de 5 a 6 miembros fusionados como se muestra en la formula (1), en el cual en dicho arilo y heteroarilo cada C sustituible del anillo está sustituido en forma independiente con R2 y cada N del anillo sustituible está sustituido en forma independiente con R6; W es N o C(R12); X es N o N-oxido; Z es S, S(=O) o S(=O)2; R1 es H, alquilo, alcoxi, hidroxi, halo -CN, S(O)n-alquilo, -C(O)NR9R10, -(CR9R10)1-6OH, o -NR4(CR9R10)1-2OR9; cada R2 se selecciona en forma independiente del grupo formado por H, halo, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, -(CR10R11)0-6-OR7, -C(O)R4, -C(S)R4, -C(O)OR7, -C(S)OR7, -OC(O)R7, -OC(S)R7, -C(O)NR4R5, -C(S)NR4R5, -C(O)NR4OR7, -C(S)NR4OR7, -C(O)NR7NR4R5, -C(S)NR7NR4R5, -C(S)NR4OR7, -C(O)SR7, - NR4R5, -NR4C(O)R5, -NR4C(S)R5, -NR4C(O)OR7, -NR4C(S)OR7, -OC(O)NR4R5, -OC(S)NR4R5, -NR4C(O)NR4R5, -NR4C(S)NR4R5, -NR4C(O)NR4OR7, -NR4C(S)NR4OR7, -(CR10R11)0-6SR7, SO2R7, -S(O)1-2NR4R5, -N(R7)SO2R7, -S(O)1-2NR5OR7, -CN, -OCF3, -SCF3, -C(=NR7)NR4, - C(O)NR7(CH2)1-10NR4R5, -C(O)NR7(CH2)1-10OR7, -C(S)NR7(CH2)1-10NR4R5, -C(S)NR7(CH2)1-10OR7, haloalquilo y alquilsililo, donde cada uno de dichos alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arlo, aralquilo, heteroarilo o heteroaralquilo está sustituido en forma opcional e independiente con 1-5 restos R9; cada R3 se selecciona en forma independiente del grupo formado por H, halo, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, -(CR10R11)0-6-OR7, -C(O)R4, -C(S)R4, -C(O)OR7, -C(S)OR7, -OC(O)R7, -OC(S)R7, -C(O)NR4R5, -C(S)NR4R5, -C(O)NR4OR7, -C(S)NR4OR7, -C(O)NR7NR4R5, -C(S)NR7NR4R5, -C(S)NR4OR7, -C(O)SR7, - NR4R5, -NR4C(O)R5, -NR4C(S)R5, -NR4C(O)OR7, -NR4C(S)OR7, -OC(O)NR4R5, -OC(S)NR4R5, -NR4C(O)NR4R5, -NR4C(S)NR4R5, -NR4C(O)NR4OR7, -NR4C(S)NR4OR7, -(CR10R11)0-6SR7, SO2R7, -S(O)1-2NR4R5, -N(R7)SO2R7, -S(O)1-2NR5OR7, -CN, -OCF3, -SCF3, -C(=NR7)NR4R5, - C(O)NR7(CH2)1-10NR4R5, -C(O)NR7(CH2)1-10OR7, -C(S)NR7(CH2)1-10NR4R5, -C(S)NR7(CH2)1-10OR7, haloalquilo y alquilsililo, donde cada uno de dichos alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arlo, aralquilo, heteroarilo o heteroaralquilo está sustituido en forma opcional e independiente con 1-5 restos R9; cada R4 y R5 se selecciona en forma independiente del grupo formado por H, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, -OR7, -C(O)R7, y -C(O)OR7, donde cada uno de dichos alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, o heteroaralquilo está sustituido en forma opcional con 1-4 restos R8; o R4 y R5, cuando están unidos al mismo átomo de N, se toman opcionalmente junto con el átomo de N al cual están unidos para formar un anillo heterocíclico de 3-6 miembros que tiene 0-2 heteroátomos adicionales seleccionados de N, O, o S; cada R6 se selecciona de forma independiente del grupo formado por H, alquilo, arilo, aralquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, heteroarilo, heteroaralquilo, -C(CH2)1-6CF3, -C(O)R7, -C(O)OR7 y -SO2R7; cada R7 se selecciona en forma independiente del grupo formado por H, alquilo, arilo, aralquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, heteroarilo, y heteroaralquilo, donde cada miembro de R7 excepto H está sustituido en forma opcional con 1-4 restos R8; cada R8 se selecciona en forma independiente del grupo formado por halo, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, -NO2, -OR10, -(alquilo c1-6)-OR10, - CN, -NR10R11, -C(O)R10, -C(O)OR10, -C(O)NR10R11, -CF3, -OCF3, -CF2CF3, -C(=NOH)R10, -N(R10)C(O)R11, -C(=NR10)NR10R11, y -NR10C(O)OR11, donde cada uno de dichos alquilo, cicloalquilo, heterociclilo, arilo, y heteroarilo está sustituido, en forma opcional en forma independiente, con 1-3 restos seleccionados del grupo formado por halo, alquilo cicloalquilo, heterociclilo, arilo, heteroarilo, -NO2, -OR10, -(alquilo C1-6)-OR10, -CN, -NR10R11, -C(O)OR10, -C(O)NR10R11, -CF3, -OCF3, -NR10C(O)OR11 y -NR10C(O)R40; o dos grupos R8, cuando están unidos al mismo átomo de C, se toman opcionalmente junto con el átomo de C al cual están unidos para formar un grupo C=O o C=S; cada R9 se selecciona en forma independiente del grupo formado por H, alquilo, alcoxi, OH, CN, halo, -(CR10R11)0-4NR4R5, haloalquilo, hidroxialquilo, alcoxialquilo, -C(O)NR4R5, -C(O)OR7, -OC(O)NR4R5, -NR4C(O)R5, y -NR4C(O)NR4R5; cada R10 es, en forma independiente, H o alquilo; o R9 y R10, cuando están unidos al mismo átomo de N, se toman opcionalmente junto con el átomo de N al cual están unidos para formar un anillo heterocíclico de 3-6 miembros que tiene 0-2 heteroátomos adicionales seleccionados de N, O, o S, cada R11 es, en forma independiente, H o alquilo; o R10 y R11, cuando están unidos al mismo átomo de N, se toman opcionalmente junto con el átomo de N al cual están unidos para formar un anillo heterocíclico de 3-6 miembros que tiene 0-2 heteroátomos adicionales seleccionados de N, O, o S; cada R12 se selecciona en forma independiente del grupo formado por H, halo, alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, -(CR10R11)0-6-OR7, -C(O)R4, -C(S)R4, -C(O)OR7, - C(S)OR7, -OC(O)R7, -OC(S)R7, -C(O)NR4R5, -C(S)NR4R5, -C(O)NR4OR7, -C(S)NR4OR7, -C(O)NR7NR4R5, -C(S)NR7NR4R5, -C(S)NR4OR7, -C(O)SR7, -NR4R5, -NR4C(O)R5, -NR4C(S)R5, -NR4C(O)OR7, -NR4C(S)OR7, -OC(O)NR4R5, -OC(S)NR4R5, -NR4C(O)NR4R5, -NR4C(S)NR4R5, - NR4C(O)NR4OR7, -NR4C(S)NR4OR7, -(CR10R11)0-6SR7, SO2R7, -S(O)1-2NR4R5, -N(R7)SO2R7, -S(O)1-2NR5OR7, -CN, -OCF3, -SCF3, -C(=NR7)NR4, -C(O)NR7(CH2)1-10NR4R5, -C(O)NR7(CH2)1-10OR7, -C(S)NR7(CH2)1-10NR4R5, -C(S)NR7(CH2)1-10OR7, haloalquilo y alquilsililo, donde cada uno de dichos alquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo está sustituido en forma opcional e independiente con 1-5 restos R9; y R40 se selecciona del grupo formado por cicloalquilo, heterociclilo, arilo y heteroarilo, donde cada uno de dichos cicloalquilo, heterociclilo, arilo y heteroarilo son de forma opcional independiente sustituido con 1-3 restos seleccionados en forma independiente del grupo formado por -CN, -OH, halo, alquilo, haloalquilo, alcoxi, y -NR10R11; con la salvedad de que el compuesto de formula (1) no incluye ninguno de los compuestos del 1 al 15, donde R20 es H, -CH3 o -OCH3 y R21 es -C(O)CH3, - C(O)CH=CH-fenilo o -C(O)CH=CH-(4-metoxifenilo); R22 y R23 son en forma independiente h o metoxi; R24 es metilo, metoxi o -Cl y R25 es -CONH2 o -CO2Et; R26 es -CO2Me, -CO2Et, -CO2H, -C(O)-fenilo, -C(O)-p-metilfenilo, -C(O)-p-bromofenilo, -C()O)CH3, - CN, -C(O)NH-fenilo, -C(O)NH-p-metoxifenilo, -C(O)NHNH2, -C(O)NH-p-clorofenilo; R27 es H, -OH, -OCH3 o -OCH(CH3)2, R28 es -OH, -OCH2CN o -OC(O)NH(CH2)5CN, y R29 es -C(O)OCH(CH3)2 o -C(O)O-ciclohexilo; R30 es como en los restos 1-5, -CO2CH3, -CO2C2H5, -C(O)NH2, -C/(O)NHNH2, o -C(O)NHCH3 y R31 es C6H5, p-OHC6H4 o p-CH3C6H4; R32 es H o NO2; R33 y R34 son en forma independiente H, -OCH3 o -OC2H5; R35 es H o -OCH3, y R36 es H, CH3 o C6H5; R37 es -CO2Me, -CO2Et, -CO2H, -C(O)NH2, -C(O)NHNH2, -CN, - C(O)NH-p-metoxifenilo, -C(O)NH-(2-piridilo o como en el resto 6; R38 es H, metilo o CF3 y R39 es SMe, SOMe, SO2Me, Cl, NH(CH2)NEt2, o N-(N'-metil)piperazinilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66013405P | 2005-03-09 | 2005-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053158A1 true AR053158A1 (es) | 2007-04-25 |
Family
ID=36581831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100851A AR053158A1 (es) | 2005-03-09 | 2006-03-07 | Compuestos para inhibir la actividad de quinesina de ksp |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060281778A1 (es) |
| EP (1) | EP1863571A1 (es) |
| JP (1) | JP2008533019A (es) |
| CN (1) | CN101171052A (es) |
| AR (1) | AR053158A1 (es) |
| CA (1) | CA2599901A1 (es) |
| MX (1) | MX2007010973A (es) |
| TW (1) | TW200700066A (es) |
| WO (1) | WO2006098962A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007011647A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin ksp |
| WO2008079293A1 (en) * | 2006-12-21 | 2008-07-03 | Schering Corporation | Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity |
| WO2009017701A2 (en) * | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| NZ583970A (en) | 2007-10-11 | 2011-04-29 | Univ California | Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase |
| EP2220061B1 (en) | 2007-10-19 | 2016-02-17 | Merck Sharp & Dohme Corp. | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity |
| US8609675B2 (en) | 2009-07-02 | 2013-12-17 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds as novel mTOR inhibitors |
| EP2473041B1 (en) | 2009-09-04 | 2018-03-07 | Merck Sharp & Dohme Corp. | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| EP2608669B1 (en) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| IN2013MN02170A (es) | 2011-04-21 | 2015-06-12 | Piramal Entpr Ltd | |
| US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
| SE1350211A1 (sv) * | 2012-02-23 | 2013-08-24 | Golden Biotechnology Corp | Metoder och kompositioner för behandling av cancermetastaser |
| WO2014144836A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Carbamate derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| WO2014144547A2 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors |
| CN105777773B (zh) * | 2015-12-25 | 2017-12-08 | 浙江师范大学 | 噻吩[2,3‑b]喹啉衍生物及其合成方法和应用 |
| CN106967086B (zh) * | 2017-03-20 | 2018-08-07 | 浙江师范大学 | 一种具有抗菌活性的喹啉并硫吡喃衍生物及其合成方法和应用 |
| KR102604900B1 (ko) | 2017-05-11 | 2023-11-21 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581448A (en) * | 1984-10-10 | 1986-04-08 | Merrell Dow Pharmaceuticals Inc. | Thienotriazines |
| JP3341288B2 (ja) * | 1990-08-17 | 2002-11-05 | 三菱ウェルファーマ株式会社 | ピリジン化合物および骨粗鬆症治療薬 |
| AU3262593A (en) * | 1992-01-11 | 1993-08-03 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
| AU9384701A (en) * | 2000-10-02 | 2002-04-15 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
| RS50504A (sr) * | 2001-11-08 | 2007-04-10 | Elan Pharmaceuticals Inc., | Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana |
| DE60222302T2 (de) * | 2001-12-06 | 2008-05-29 | Merck & Co., Inc. | Inhibitoren von mitotischem kinesin |
| DE10164139A1 (de) * | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| EP1534693A2 (en) * | 2002-09-06 | 2005-06-01 | Elan Pharmaceuticals, Inc. | 1, 3-diamino-2-hydroxypropane prodrug derivatives |
| US7345046B2 (en) * | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
-
2006
- 2006-03-07 AR ARP060100851A patent/AR053158A1/es not_active Application Discontinuation
- 2006-03-07 EP EP06737332A patent/EP1863571A1/en not_active Withdrawn
- 2006-03-07 CN CNA200680015599XA patent/CN101171052A/zh active Pending
- 2006-03-07 WO PCT/US2006/008150 patent/WO2006098962A1/en not_active Ceased
- 2006-03-07 CA CA002599901A patent/CA2599901A1/en not_active Abandoned
- 2006-03-07 MX MX2007010973A patent/MX2007010973A/es not_active Application Discontinuation
- 2006-03-07 JP JP2008500853A patent/JP2008533019A/ja active Pending
- 2006-03-07 US US11/369,625 patent/US20060281778A1/en not_active Abandoned
- 2006-03-08 TW TW095107698A patent/TW200700066A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060281778A1 (en) | 2006-12-14 |
| CN101171052A (zh) | 2008-04-30 |
| EP1863571A1 (en) | 2007-12-12 |
| MX2007010973A (es) | 2007-09-19 |
| TW200700066A (en) | 2007-01-01 |
| WO2006098962A1 (en) | 2006-09-21 |
| JP2008533019A (ja) | 2008-08-21 |
| CA2599901A1 (en) | 2006-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053158A1 (es) | Compuestos para inhibir la actividad de quinesina de ksp | |
| NZ754994A (en) | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| CY1121231T1 (el) | Παραγωγο τετραϋδροϊμιδαζο[1,5-d][1,4]οξαζεπινης | |
| AR108557A1 (es) | Uracilpiridinas herbicidas | |
| ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
| AR052682A1 (es) | DERIVADOS DE 5, 6, 7, 8 - TETRAHIDROTIEN[2, 3 - B]QUINOLINA uTILES PARA INHIBIR LA ACTIVIDAD DE QUINESINA DE KSP, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS. | |
| PE20070855A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| ME02583B (me) | Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze | |
| AR103965A1 (es) | Derivados de pirimidiniloxi piridina sustituida como herbicidas | |
| AR049092A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
| AR081978A1 (es) | Derivados fusionados de pirimidina para la inhibicion de la actividad quinasa de tirosina | |
| AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
| PE20060648A1 (es) | Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| CY1109821T1 (el) | Ενωσεις πιπεραζινης με ζιζανιοκτονα δραση | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
| AR103397A1 (es) | Oxoborazoles microbicidas | |
| MX2010008362A (es) | Derivados de heteroarilamida diazepinopirimidona sustituidos. | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |